We examined the impact of pretreatment neutrophil count on survival in patients with advanced non-small-cell lung cancer (NSCLC). A total of 388 chemo-naïve patients with stage IIIB or IV NSCLC from a randomized controlled trial were evaluated. The effects of pretreatment peripheral blood neutrophil, lymphocyte and monocyte counts and neutrophil-lymphocyte ratio on survival were examined using the proportional hazards regression model to estimate hazard ratios after adjustment for covariates. The optimal cut-off value was determined by proportional hazards regression analysis with the minimum P-value approach and shrinkage procedure. After adjustment for prognostic factors, the pretreatment elevated neutrophil count was statistically significantly associated with short overall (P=0.0008) and progression-free survival (P=0.024), whereas no association was found between prognosis and lymphocyte or monocyte count. The cut-off value selected for neutrophil count was 4500/mm 3 (corrected hazard ratio: 1.67, 95% confidence interval (CI), 1.09-2.54). The median survival time was 19.3 months (95%CI, 16.5-21.4) for the low-neutrophil group (<4500/mm 3 , n=204) and 10.2 months (95%CI, 8.0-12.3) for the high-neutrophil group (>4500/mm 3 , n=184). We confirmed that pretreatment elevated neutrophil count is an independent prognostic factor in patients with advanced NSCLC receiving modern chemotherapy. Neutrophil count is easily measured at low cost, and it may be a useful indicator of patient prognosis.
Introduction
The prognosis for patients with advanced non-small-cell lung cancer (NSCLC) (TNM stage IIIB with a positive pleural effusion, or stage IV) has improved with recent advances in systemic chemotherapy, but still remains poor, with a median overall survival time between 4 and 15 months. 1 Prognostic factors identified in previous studies include tumour stage, performance status (PS), weight loss, sex, plasma lactate dehydrogenase (LDH) level and the presence of bone, liver or skin metastases. 2 Although novel immunological and histological biomarkers have been identified, these are often time-consuming to measure, and this is not part of standard practice.
It is now evident that inflammatory cells in the tumour microenvironment have significant effects on tumour development. [3] [4] [5] [6] Elevation in the pretreatment neutrophil count has been proposed as a prognostic factor for poor survival in patients with metastatic renal cell carcinoma, [7] [8] [9] and elevated neutrophil, monocyte or leukocyte count has been associated with poor survival in patients with metastatic melanoma. 10, 11 A high neutrophil-lymphocyte ratio may be related to poor prognosis in patients with colorectal cancer 12 and in those with advanced gastric cancer. 13 The European Lung Cancer Working Group found that the high-neutrophil count was an independent prognostic factor for poor survival in patients with unresectable advanced NSCLC 14 and in those with small-cell lung cancer. 15 A retrospective study found that neutrophil count was of prognostic value in patients with lung cancer. 16 The aim of this study was to examine and confirm the impact of pretreatment peripheral blood neutrophil, monocyte and lymphocyte counts on overall and progression-free survival in a well-defined population of patients with advanced NSCLC being treated with regimens using newer chemotherapeutic agents in a randomized controlled clinical trial. 
Patients and methods

Study population
Statistical analysis
Overall survival was defined as the time from randomisation until death from any cause, and progression-free survival was defined as the time from randomisation until objective tumour progression or death. Survival curves were estimated with the Kaplan-Meier method. Associations between the factors and the prognosis were examined with the log-rank test in univariate analyses. The prognostic impact of pretreatment peripheral blood neutrophil, lymphocyte and monocyte counts, and neutrophil-lymphocyte ratio were examined using the proportional hazards regression model to estimate hazard ratios after adjustment for covariates without variable selection. Optimal cut-off points for continuous variables were selected using the minimum P-value approach with correction of the P-value. 18 The corrected hazard ratio and its 95% confidence interval (CI) were estimated using a shrinkage procedure with bootstrap resampling. 19 All statistical analyses were done using SAS version 9.1 (SAS Institute, Cary, NC). 
Results
Patient characteristics
Relationship between pretreatment neutrophil, lymphocyte and monocytes counts and survival
In univariate analyses, pretreatment elevated counts of neutrophils were statistically significantly associated with short overall (Fig. 1A, P<0 .0001) and
progression-free survival (Fig. 1B, P=0 .0001). Although lymphocyte count did not correlate with survival, there were significant relationships between high-neutrophil-lymphocyte ratio and short overall (P<0.0001) and
progression-free survival (P=0.005). The elevated monocyte count was also significantly associated with short overall survival (P=0.004), and moderately related to short progression-free survival (P=0.052). We selected sex, smoking history, stage, ECOG PS, weight loss, plasma LDH and presence of bone, liver or skin metastases as the known pretreatment prognostic factors. 2, 14 Adjusted hazard ratios for the relationship between pretreatment neutrophil, lymphocyte and monocyte counts and neutrophil-lymphocyte ratio and overall and progression-free survival after adjustment for the known prognostic factors are shown in Table 2 . There was a statistically significant association between elevated neutrophil count and short overall (P=0.0008) and progression-free survival (P=0.024), and between high-neutrophil-lymphocyte ratio and short overall (P=0.011) and progression-free survival (P=0.040), whereas no association was found between lymphocyte or monocyte count and prognosis.
The relationship between neutrophil count and both overall and progression-free survival was linear, whereas the relationship between neutrophil-lymphocyte ratio and overall survival was to some degree non-linear.
Optimal cut-off value for pretreatment neutrophil count
In selecting optimal cut-off values for the effect of neutrophil count on overall survival, the range between the 5th percentile (2205/mm 3 ) and the 95th percentile (9657/mm 3 ) for distribution of neutrophils was selected, and the possible cut-off points at intervals of 500/mm 3 from 2500/mm 3 to 9500/mm 3 were considered (giving 15 candidate cut-off points). Using the minimum P-value approach, the selected cut-off value for neutrophil count was 4500/mm 3 (corrected P=0.0009) and the corrected shrunk hazard ratio was 1.67 (95%CI, 1.09-2.54, from 100 bootstrap samples; Table 3 ). The selected optimal cut-off value did not change even if we used the stratified proportional hazards model, . There was no interaction between the neutrophil count and the treatment arms (P for interaction = 0.437).
Relationship between pretreatment neutrophil count and intensity of chemotherapy
In order to evaluate the effect of neutrophil count on administration of chemotherapy and toxicity, we analysed the dose intensity of chemotherapeutic agents and the incidence of toxicity in each arm. In the VGD arm, there was no The toxicity due to treatment was also analysed. In the VGD arm, the incidence of grade 3 or 4 non-hematological toxicity within the first three cycles of treatment was significantly higher in the high-neutrophil group than in the low-neutrophil group (26.5% versus 8.5%; P=0.002, Fisher's exact test).
Significantly fewer cycles were administered in the high-neutrophil group than in 
Discussion
In multivariate analysis after adjustment for known prognostic factors, we found linear associations between pretreatment elevated neutrophil count and short overall and progression-free survival. As there was no such association for the lymphocyte count, the relationship between neutrophil-lymphocyte ratio and overall survival was also found, however it was to some degree weak and non-linear. As a consequence, we consider that absolute neutrophil count may better serve as a prognostic factor. An optimal cut-off value for the relationship between neutrophil count and overall survival was identified as 4500/mm 3 (corrected hazard ratio, 1.67; 95%CI, 1.09-2.54). In the VGD arm, the low-neutrophil group (<4500/mm 3 ) tended to have a lower incidence of severe non-hematological toxicity and tolerated longer administration of the chemotherapeutic agents compared with the high-neutrophil group. However, no such association was found in the PC arm, and pretreatment neutrophil count was equally predictive of prognosis in both treatment arms when analysed separately. We therefore do not consider it likely that the pretreatment neutrophil count serves as an indicator of intolerance to chemotherapy, rather than as an indicator of poor prognosis.
A number of studies in the last two decades have suggested an association between the neutrophil count or neutrophil-lymphocyte ratio and the prognosis of cancer patients, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] although no acceptable explanations for the mechanisms underlying these observed associations have been proposed. Moreover, although neutrophilia often accompanies the diagnosis of cancer, the causes of neutrophilia in cancer patients are not fully understood, and are likely to be the result of a combination of factors. One obvious cause of neutrophilia is paraneoplastic production of myeloid growth factors by cancer cells themselves.
Granulocyte-colony stimulating factor (G-CSF) is a growth factor that acts selectively on bone marrow granulocytic lineage cells, and is considered to play a central role in granulopoiesis. Administration of G-CSF was reported to increase bone marrow neutrophil precursors and shorten bone marrow transit time in mice and humans, [20] [21] [22] resulting in marked increases in the production of neutrophils. Granulocyte-macrophage colony stimulating factor (GM-CSF) and macrophage-colony stimulating factor are other examples of hematopoietic growth factors that cause neutrophilia by in vivo administration. 23, 24 A variety of non-hematopoietic malignant tumours including mesothelioma, 25 squamous cell carcinoma of the oropharynx, 26 melanoma, 27 glioblastoma, 28 and carcinoma of the lung 29 The association between cancer and inflammation was initially pointed out during the 19th century. However, recent advances in understanding of tumour biology have stimulated renewed interests in searching for links between cancer and inflammation. [3] [4] [5] [6] Today, it is widely accepted that chronic inflammation contributes to the initiation and progression of cancer. Furthermore, it is now known that inflammatory processes almost always accompany cancer, and persistence of chronic inflammation-like processes within cancer tissue causes suppression of anti-tumour immunity by several mechanisms such as activation of type 2 T-helper responses, recruitment of regulatory T cells and activation of the chemokine system, and result in promotion of cancer growth and metastasis.
Thus, inflammation may result in the aggressive growth of a tumour. The cytokines interleukin (IL)-6 and tumour necrosis factor-alpha (TNFα), which are implicated in the pathogenesis of cancer-related inflammation as well as of acute inflammatory processes, are also known to induce neutrophilia. [32] [33] [34] It is possible that the neutrophil count at diagnosis indicates the severity or nature of inflammation occurring within the tumour, and thus reflects prognosis. In a recent report, a proportion of patients with metastatic cancer were shown to have IL-6-mediated elevation in serum cortisol levels. This may partly explain the neutrophilia of cancer patients, although its contribution to outcome is not yet known. 35 We did not measure inflammatory markers such as C-reactive protein or hemogram of total white cell count in this study. However, we are investigating correlations between several cytokines and prognosis in a correlative study of another clinical trial (ClinicalTrials.gov identifier NCT00616031).
Besides inflammation in cancer tissue, host factors may influence the prognosis of cancer patients. It is now known that lifetime exposure to infectious diseases and other sources of inflammation is not only related to the pathogenesis of cancer, but also plays an important role in aging and influences longevity. 36, 37 Aging is a complex process, and numerous genes are known to have associations with longevity. 38 Polymorphisms of the genes that encode proteins involved in inflammatory processes (e.g., IL-1, IL-6, IL-10 and TNFα) are suspected to affect aging and longevity. Given the close relationship between cancer and inflammation, it is natural to speculate that genetic polymorphisms in inflammation-related genes may also influence host responses to cancer and prognosis; peripheral neutrophil count may be an indicator of this association.
Another possibility is that neutrophil directly down-regulates host cellular immunity against cancer, thereby affecting the prognosis. In vitro studies showed that neutrophils suppress the cytolytic activity of lymphocytes and natural killer cells when co-cultured with neutrophils and lymphocytes from normal healthy donors; the degree of suppression was proportional to the number of neutrophils added. [39] [40] [41] The clinical relevance of these effects seen in 13 in vitro studies is currently unknown. The biological basis for the multi-factorial and complex association is also unknown, and merits further research.
Conclusion
Using the dataset from a randomised controlled trial, we have confirmed that pretreatment peripheral blood neutrophil count is an independent prognostic factor in patients with advanced NSCLC receiving modern chemotherapy. The results need to be investigated for generalisability in other populations. Since neutrophil count is easily measured at low cost, it may be a useful predictor of prognosis in clinical practice. Considering the strength of the association reported here, neutrophil count should be taken into account as a stratification factor in future randomised clinical trials of patients with advanced NSCLC.
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